Journal articleCancer Med2023

Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.

DOI 10.1002/cam4.5290 ↗ Europe PMC, retrieved 5 November 2026

Journal: Cancer Med
Published: 8 October 2022
Citations: 10
License: cc by

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 1

Builds on itMesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated M… NCT02810418 ↗

Grants 5

Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies ZIABC008753 ↗
Adoptive cell therapy for malignant mesothelioma and other mesothelin expressing ZIABC010816 ↗
Precision Therapy to Target Pancreatic Ductal Adenocarcinoma ZIABC011652 ↗
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies ZICSC006537 ↗
Signal Transduction Events and the Regulation of Cell Growth ZICSC006743 ↗